IRCT20211104052965N1
Recruiting
Phase 4
Investigating the effect of empagliflozin on renal events in non-diabetic chronic kidney disease patients with and without proteinuria. A double-blind placebo-controlled randomized clinical trial study
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Chronic kidney disease.
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 458
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients over 18 years old
- •Patients with 20\=eGFR\=75 mL/min/1\.73m2 (calculated by MDRD formula) at the first visit
Exclusion Criteria
- •Dominant or autosomal recessive polycystic kidney disease, lupus nephritis or vasculitis with anti\-neutrophil cytoplasmic antibody (ANCA)
- •Received cytotoxic therapy, immunosuppressive therapy, or other immunologic therapy for primary or secondary renal disease within 6 months prior to the first visit
- •Organ transplant history
- •Blood pressure less than 90/60 mmHg
- •Treatment with a sodium glucose cotransporter (SGLT 2\) inhibitor within 8 weeks before the first visit or previous drug intolerance
- •Frequent UTI
- •Type 1 and 2 diabetes
- •Class (NYHA) IV congestive heart failure at first visit
- •Myocardial infarction, unstable angina, stroke and transient ischemic attack (TIA) within 12 weeks before the first visit
- •Cardiovascular interventions such as CABG, PCI and valve replacement or repair within 12 weeks before the first visit
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Effect of Empagliflozin in diabetic nephropathyephropathy and proteinuria in diabetic nephropathy patients taking empagliflozin.Diabetes mellitus due to underlying condition with diabetic nephropathyE08.21IRCT20210906052395N1Shahid Beheshti University of Medical Sciences96
Active, Not Recruiting
Phase 1
Effect of treatment with Empagliflozin alone or in combination with Semaglutide on protein in the urine in persons with type 2 diabetes and elevated urinary protein.Type 2 diabetes with renal complicationsMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-003175-19-DKSteno Diabetes Center Copenhagen80
Active, Not Recruiting
Phase 1
Effects of empagliflozin on urine output and renal function in patients with acute heart failureacute decompensated heart failureMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-003692-35-DEFriedrich Schiller University Jena60
Recruiting
Phase 2
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsEnd Stage Renal Disease on DialysisPeritoneal Dialysis ComplicationSodium-glucose Cotransporter-2 InhibitorResidual Kidney FunctionNCT06483074Chinese University of Hong Kong48
Completed
N/A
Effects of dapagliflozin on renal function in patients with type 2 diabetes [Diamond study-4]patients with type 2 diabetesJPRN-UMIN000020185Diamond study group15